Wave Life Sciences, Inc. (WVE) stock
WVENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 10/3046% below fair value
$2.84−0.03 (-1.05%)
Close on Nov 17, 2026Market cap $560.13MP/E –Yield –
Wave Life Sciences total assets
Total assets on the balance sheet at the end of each period.
Wave Life Sciences's total assets was $507.93M at Sep 30, 2026. For fiscal 2025 it was $638.50M, up 81.3% from the year before. Over ten years it grew 14.5% a year on average. The highest annual figure on record is $638.50M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $638.50M | +81.3% |
| FY2024 | Dec 31, 2024 | $352.21M | +28.1% |
| FY2023 | Dec 31, 2023 | $274.95M | +87.8% |
| FY2022 | Dec 31, 2022 | $146.39M | -29.3% |
| FY2021 | Dec 31, 2021 | $207.01M | -25.9% |
| FY2020 | Dec 31, 2020 | $279.24M | -1.8% |
| FY2019 | Dec 31, 2019 | $284.25M | -4.0% |
| FY2018 | Dec 31, 2018 | $295.94M | +62.7% |
| FY2017 | Dec 31, 2017 | $181.84M | +10.3% |
| FY2016 | Dec 31, 2016 | $164.81M | -0.4% |
| FY2015 | Dec 31, 2015 | $165.42M | +5530.5% |
| FY2014 | Dec 31, 2014 | $2.94M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $507.93M | +110.4% |
| Q2 FY2026 | Jun 30, 2026 | $558.32M | +121.2% |
| Q1 FY2026 | Mar 31, 2026 | $583.54M | +102.4% |
| Q4 FY2025 | Dec 31, 2025 | $638.50M | +81.3% |
| Q3 FY2025 | Sep 30, 2025 | $241.38M | -32.7% |
| Q2 FY2025 | Jun 30, 2025 | $252.36M | +20.8% |
| Q1 FY2025 | Mar 31, 2025 | $288.34M | +22.6% |
| Q4 FY2024 | Dec 31, 2024 | $352.21M | +28.1% |
| Q3 FY2024 | Sep 30, 2024 | $358.50M | +79.3% |
| Q2 FY2024 | Jun 30, 2024 | $208.82M | -9.2% |
| Q1 FY2024 | Mar 31, 2024 | $235.27M | -12.0% |
| Q4 FY2023 | Dec 31, 2023 | $274.95M | +87.8% |
| Q3 FY2023 | Sep 30, 2023 | $199.92M | +10.1% |
| Q2 FY2023 | Jun 30, 2023 | $229.99M | +7.8% |
| Q1 FY2023 | Mar 31, 2023 | $267.27M | +59.7% |
| Q4 FY2022 | Dec 31, 2022 | $146.39M | -29.3% |
| Q3 FY2022 | Sep 30, 2022 | $181.51M | -9.5% |
| Q2 FY2022 | Jun 30, 2022 | $213.32M | +3.3% |
| Q1 FY2022 | Mar 31, 2022 | $167.36M | -31.0% |
| Q4 FY2021 | Dec 31, 2021 | $207.01M | -25.9% |
| Q3 FY2021 | Sep 30, 2021 | $200.51M | -35.3% |
| Q2 FY2021 | Jun 30, 2021 | $206.41M | +1.2% |
| Q1 FY2021 | Mar 31, 2021 | $242.65M | +1.7% |
| Q4 FY2020 | Dec 31, 2020 | $279.24M | -1.8% |
| Q3 FY2020 | Sep 30, 2020 | $310.06M | -10.7% |
| Q2 FY2020 | Jun 30, 2020 | $203.95M | -47.1% |
| Q1 FY2020 | Mar 31, 2020 | $238.57M | -44.6% |
| Q4 FY2019 | Dec 31, 2019 | $284.25M | -4.0% |
| Q3 FY2019 | Sep 30, 2019 | $347.21M | +7.0% |
| Q2 FY2019 | Jun 30, 2019 | $385.55M | +9.0% |
| Q1 FY2019 | Mar 31, 2019 | $430.61M | +186.3% |
| Q4 FY2018 | Dec 31, 2018 | $295.94M | +62.7% |
| Q3 FY2018 | Sep 30, 2018 | $324.58M | +60.6% |
| Q2 FY2018 | Jun 30, 2018 | $353.74M | +56.2% |
| Q1 FY2018 | Mar 31, 2018 | $150.42M | -0.7% |
| Q4 FY2017 | Dec 31, 2017 | $181.84M | +10.3% |
| Q3 FY2017 | Sep 30, 2017 | $202.09M | – |
| Q2 FY2017 | Jun 30, 2017 | $226.43M | – |
| Q1 FY2017 | Mar 31, 2017 | $151.51M | – |
| Q4 FY2016 | Dec 31, 2016 | $164.81M | – |
See a number that looks wrong?